STOCK TITAN

Arrowhead Pharma - ARWR STOCK NEWS

Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a leading clinical-stage biotechnology company dedicated to developing innovative medicines that address intractable diseases through gene silencing. The company utilizes an extensive array of RNA chemistries and efficient delivery systems to harness the power of RNA interference (RNAi) mechanisms. This approach allows for the rapid, deep, and durable knockdown of target genes, thereby reducing the production of specific proteins that cause diseases.

Arrowhead's groundbreaking therapies are at the forefront of genetic-based treatments, presenting potential life-changing solutions for patients. Notable among their technologies is the Targeted RNAi Molecule (TRiMTM) platform. This platform employs ligand-mediated delivery for tissue-specific targeting while maintaining structural simplicity. The TRiMTM platform is built upon over a decade of research in actively targeted drug delivery, offering advantages such as simplified manufacturing processes and enhanced specificity.

The company's diverse portfolio includes promising treatments for conditions such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular diseases. Arrowhead is continuously engaged in advancing its clinical programs and forging strategic partnerships to bring its novel therapies to market.

With headquarters in Pasadena, California, Arrowhead Pharmaceuticals remains committed to transforming the landscape of genetic medicine and improving patient outcomes worldwide. Their dedication to scientific innovation and patient care positions them as a pivotal player in the biotechnology sector.

Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in several key upcoming events in June 2021. Highlights include:

  • Jefferies Virtual Healthcare Conference: June 3, 2:30 p.m. ET - Fireside chat with CEO Chris Anzalone.
  • Goldman Sachs Global Healthcare Conference: June 10, 2:10 p.m. ET - Fireside chat with CEO Chris Anzalone.
  • The International Liver Congress 2021: June 23-26 - Presentations on ARO-HSD and ARO-AAT, among others.

For more details, visit Arrowhead's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported that Janssen Pharmaceuticals has exercised its option for ARO-JNJ1, leading to a $10 million option exercise fee for Arrowhead. This agreement, part of a collaboration initiated in 2018, allows Janssen to develop and commercialize ARO-JNJ1, an RNAi therapeutic candidate. Arrowhead anticipates additional milestone payments and royalties from the commercial sales of ARO-JNJ1. The CEO expressed optimism about the collaboration, highlighting its productivity in addressing chronic hepatitis B and potential future programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is set to participate in major healthcare events in May 2021. Key dates include the RBC Capital Markets Global Healthcare from May 18-20, with a presentation by CEO Chris Anzalone on May 18 at 11:30 a.m. ET, and the UBS Global Healthcare Virtual Conference from May 24-26, featuring another chat by Anzalone on May 26 at 3:00 p.m. ET. For presentation materials and details, visit the Arrowhead website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
Rhea-AI Summary

Arrowhead Pharmaceuticals (ARWR) reported its fiscal second-quarter financials for the period ending March 31, 2021. The company achieved a revenue of $32.8 million, up from $23.5 million in the previous year, resulting in a net loss of $26.8 million compared to $19.8 million in the same quarter last year. Operating expenses increased to $61 million, driven by research and development costs. Significant clinical updates include positive interim results for the ARO-AAT therapy and submissions for INDs for ARO-ANG3 and ARO-APOC3 treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced promising interim results from its AROAAT2002 Phase 2 clinical study of ARO-AAT, an RNAi therapeutic for alpha-1 antitrypsin deficiency (AATD). After 48 weeks, 80% of patients showed significant improvement in fibrosis, while total intra-hepatic Z-AAT decreased by 77-97%. Following 24 weeks of treatment, two patients also improved. Arrowhead plans to share further data at a medical congress and is pursuing accelerated approval pathways. The collaboration with Takeda continues to deliver encouraging outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021. Investors can join via the company's website or by dialing in. A replay will be available after the call for 90 days. Arrowhead is focused on developing RNAi-based therapeutics aimed at treating intractable diseases through gene silencing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences earnings
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced ARO-DUX4, its first muscle-targeted investigational RNAi therapeutic candidate, aimed at treating facioscapulohumeral muscular dystrophy (FSHD). ARO-DUX4 targets the DUX4 gene, a known cause of muscle degeneration in FSHD. Preclinical data, to be presented at the 28th Annual FSHD Society International Research Congress, indicates ARO-DUX4 can reduce DUX4 expression by over 70%. Arrowhead plans to file for regulatory clearance in Q3 2021 for clinical studies, enhancing its pipeline beyond liver-targeted therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the submission of an Investigational New Drug Application (IND) for ARO-APOC3, aimed at treating hypertriglyceridemia. Initial studies showed up to a 92% reduction in triglycerides after two doses. Pending FDA review, the company plans to launch Phase 2b and Phase 3 clinical trials targeting severe hypertriglyceridemia and mixed dyslipidemia. These advancements underscore the potential of ARO-APOC3 as a new treatment for patients experiencing severe triglyceride elevation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its fiscal first quarter results for the period ended December 31, 2020. The company generated $21.3 million in revenue, down from $29.5 million in the same quarter of 2019. Operating expenses increased to $45.4 million, leading to a net loss of $20.7 million or $0.20 per share, compared to a loss of $2.7 million or $0.03 per share in the previous year. The firm is advancing its clinical pipeline with ongoing trials and collaborations, including a significant agreement with Takeda.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.81%
Tags
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an Investigational New Drug Application to the FDA for a Phase 2b study of ARO-ANG3, targeting mixed dyslipidemia. The trial aims to evaluate the safety and efficacy of the RNA interference therapeutic, focusing on reducing triglycerides and LDL cholesterol. The upcoming AROANG3-2001 study will enroll 180 participants to establish an effective dosing regimen. CMO Javier San Martin emphasized the need for new therapies in cardiovascular care, highlighting promising preliminary clinical data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags

FAQ

What is the current stock price of Arrowhead Pharma (ARWR)?

The current stock price of Arrowhead Pharma (ARWR) is $19.9 as of February 21, 2025.

What is the market cap of Arrowhead Pharma (ARWR)?

The market cap of Arrowhead Pharma (ARWR) is approximately 2.6B.

What is the primary focus of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals focuses on developing gene-silencing therapies to treat intractable diseases by targeting the genes that cause them.

What is RNA interference (RNAi)?

RNA interference (RNAi) is a natural mechanism in living cells that inhibits the expression of specific genes, thereby affecting the production of certain proteins.

What is the TRiMTM platform?

The TRiMTM platform is Arrowhead's targeted RNAi molecule technology that uses ligand-mediated delivery for tissue-specific targeting, designed to simplify manufacturing and improve therapeutic precision.

Which diseases does Arrowhead Pharmaceuticals address?

Arrowhead's treatments target diseases such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Where is Arrowhead Pharmaceuticals headquartered?

Arrowhead Pharmaceuticals is headquartered in Pasadena, California.

What are the latest developments at Arrowhead Pharmaceuticals?

For the latest news and developments, visit Arrowhead Pharmaceuticals' official website or check recent press releases and updates.

How does Arrowhead's technology benefit patients?

Arrowhead's RNAi-based therapies aim to reduce the production of proteins that cause diseases, offering potential life-changing treatments for patients.

What are some advantages of the TRiMTM platform?

The TRiMTM platform's advantages include simplified manufacturing processes and enhanced tissue-specific targeting.

Is Arrowhead publicly traded?

Yes, Arrowhead Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol ARWR.

How can I invest in Arrowhead Pharmaceuticals?

You can invest in Arrowhead Pharmaceuticals by purchasing shares through a stockbroker or an online trading platform. The company's ticker symbol is ARWR.
Arrowhead Pharma

Nasdaq:ARWR

ARWR Rankings

ARWR Stock Data

2.60B
108.23M
4.47%
79.71%
7.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA